Study finds weight-loss medications could ease migraines and cut asthma flare-ups

New research suggests that widely used weight-loss medications may offer benefits beyond obesity management, with studies indicating potential improvements in both migraine symptoms and asthma control.

The findings, presented at the European Congress on Obesity in Turkey, add to growing evidence that GLP-1 receptor agonist drugs — including semaglutide, marketed under brands such as Wegovy — may have wider therapeutic effects than originally intended.

In one large-scale study, researchers analysed Danish health registry data from 2022 to 2024 involving around 150,000 people who began treatment with Wegovy for weight management. Of these, approximately 6,800 had a prior prescription for migraine medication.

The study found that among women with a history of migraines, starting semaglutide was associated with a 7% reduction in the use of triptan-class drugs — commonly prescribed to treat acute migraine attacks — within one year of treatment initiation.

Researchers noted that the decline in migraine medication use was gradual and only observed in female patients, suggesting a possible sex-specific response that requires further investigation.

In a separate nationwide Danish cohort study involving 27,523 people with asthma who were also overweight, obese or living with type 2 diabetes, GLP-1 drug use was linked to a 26% reduction in asthma exacerbations.

The same analysis also showed a 14% decrease in the use of reliever inhalers, along with reductions in inhaled corticosteroid use and pneumonia-related events.

Experts said the improvements may be partly explained by weight loss itself, which can reduce inflammation and ease breathing difficulties in patients with obesity-related asthma.

Dr Kjell Erik Julius Hakansson, one of the study’s authors, said excess body fat creates a chronic inflammatory state that can worsen respiratory symptoms, adding that inflammation linked to obesity may differ from the allergic inflammation typically seen in asthma.

He also noted that as GLP-1 therapies become more widely used, researchers are increasingly identifying effects that extend beyond weight loss alone.

While the findings are promising, experts caution that more research is needed to confirm whether the drugs directly improve migraine and asthma outcomes or whether the benefits are primarily driven by weight reduction and related metabolic changes.